Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible

NCT02261779 is registered in ClinicalTrials.gov with Martin-Luther-Universität Halle-Wittenberg as lead sponsor.

NCT NCT02261779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02261779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible
Lead sponsor
Martin-Luther-Universität Halle-Wittenberg
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
September 30, 2017
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml